New York Life Investment Management LLC Purchases 1,378 Shares of Amgen Inc. $AMGN

New York Life Investment Management LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 1.6% in the 3rd quarter, Holdings Channel reports. The firm owned 88,055 shares of the medical research company’s stock after buying an additional 1,378 shares during the quarter. New York Life Investment Management LLC’s holdings in Amgen were worth $37,116,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. 71 West Capital Partners raised its position in Amgen by 7.9% in the third quarter. 71 West Capital Partners now owns 3,914 shares of the medical research company’s stock worth $1,650,000 after purchasing an additional 288 shares in the last quarter. Pinion Investment Advisors LLC acquired a new stake in Amgen during the third quarter valued at approximately $207,000. Leuthold Group LLC boosted its holdings in Amgen by 9.2% during the third quarter. Leuthold Group LLC now owns 22,409 shares of the medical research company’s stock valued at $9,446,000 after purchasing an additional 1,897 shares in the last quarter. Fulcrum Asset Management LLP boosted its holdings in Amgen by 65.5% during the third quarter. Fulcrum Asset Management LLP now owns 4,428 shares of the medical research company’s stock valued at $1,876,000 after purchasing an additional 1,752 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Amgen by 16.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 112,799 shares of the medical research company’s stock valued at $45,940,000 after purchasing an additional 16,327 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Guggenheim increased their target price on Amgen from $378.00 to $435.00 and gave the stock a “neutral” rating in a report on Thursday, November 5th. Leerink Partners raised their target price on Amgen from $395.00 to $464.00 and gave the stock a “market perform” rating in a research report on Thursday, November 5th. Sanford C. Bernstein boosted their price target on Amgen from $345.00 to $400.00 and gave the company a “market perform” rating in a research note on Wednesday, November 4th. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. Finally, Royal Bank Of Canada increased their price objective on Amgen from $430.00 to $470.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Amgen has an average rating of “Hold” and an average target price of $422.76.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $465.23 on Wednesday. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99. The company has a 50-day moving average of $423.79 and a two-hundred day moving average of $379.39. The company has a market cap of $251.65 billion, a PE ratio of 26.99, a P/E/G ratio of 3.25 and a beta of 0.43. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. Amgen’s revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.64 earnings per share. As a group, equities analysts expect that Amgen Inc. will post 23.33 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen’s dividend payout ratio is currently 58.47%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.